X0306 4 2023-02-28 0 0000818686 TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA 0001726096 Daniell Richard C/O TEVA PHARMACEUTICAL INDUSTRIES LTD. 124 DVORA HANEVI'A ST., TEL AVIV L3 6944020 ISRAEL 0 1 0 0 Exec. VP, European Commercial Ordinary Shares 2023-02-28 4 M 0 20598 A 63780 D Ordinary Shares 2023-02-28 4 S 0 20598 9.8866 D 43182 D Ordinary Shares 2023-02-28 4 M 0 50242 A 93424 D Ordinary Shares 2023-02-28 4 S 0 23654 9.8866 D 69770 D Restricted Share Units 2023-02-28 4 M 0 20598 0.00 D Ordinary Shares 20598 20599 D Restricted Share Units 2023-02-28 4 M 0 50242 0.00 D Ordinary Shares 50242 0 D The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.86 to $9.94, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. Restricted share units were granted on February 28, 2020 with 20,598 vested on each of February 28, 2021, February 28, 2022 and February 28, 2023, and 20,599 vesting on February 28, 2024. Restricted share units were granted on February 7, 2023 pursuant to the satisfaction of performance criteria and vested on February 28, 2023. /s/ Dov Bergwerk as attorney-in-fact for Richard Daniell 2023-03-02